SMTL ID : 4tz4.1

Crystal Structure of Human Cereblon in Complex with DDB1 and Lenalidomide

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 3.01 Å

Oligo State

hetero-1-1-mer

Ligands

1 x ZN: ZINC ION(Non-covalent)

ZN.1: 4 residues within 4Å: Chain B: C.276, C.279, C.344, C.347 4 PLIP interactions: 4 interactions with chain B Metal complexes: B:C.276, B:C.279, B:C.344, B:C.347

1 x LVY: S-Lenalidomide(Non-covalent)

LVY.2: 9 residues within 4Å: Chain B: N.304, P.305, H.306, H.331, S.332, W.333, W.339, W.353, F.355 11 PLIP interactions: 11 interactions with chain B Hydrophobic interactions: B:N.304, B:W.333, B:W.339, B:W.339, B:W.353, B:F.355 Hydrogen bonds: B:N.304, B:H.331, B:H.331, B:W.333 pi-Stacking: B:W.339

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Chamberlain, P.P. et al., Structural Basis for Responsiveness to Thalidomide-Analog Drugs Defined by the Crystal Structure of the Human Cereblon:DDB1:Lenalidomide Complex. To Be Published

Release Date

2014-08-06

Peptides

DNA damage-binding protein 1: A
Protein cereblon: B

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

B
C

DNA damage-binding protein 1

Protein cereblon